TOLAK (fluorouracil) by Pfizer is nucleic acid synthesis inhibitors [moa]. First approved in 2015.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
TOLAK (fluorouracil) is a topical cream containing a nucleoside metabolic inhibitor that disrupts nucleic acid synthesis in rapidly dividing cells. It is indicated for actinic keratosis and other skin lesions, applied directly to affected areas. The drug works by inhibiting thymidylate synthase, preventing DNA synthesis in target cells.
Product is at peak maturity with moderate competitive pressure (30%), suggesting stable but not expanding team resources.
Nucleic Acid Synthesis Inhibitors
Nucleoside Metabolic Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Worked on TOLAK at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moTOLAK offers career opportunities primarily in field-based commercial roles and medical affairs for a mature, stable dermatology product. Career growth is likely incremental rather than expansionary given peak lifecycle stage and flat clinical pipeline.